DINAMIKA FUNKTsIONAL'NYKh POKAZATELEY SUSTAVNOGO SINDROMA U BOL'NYKh OSTEOARTROZOM POD VLIYaNIEM RAZLIChNYKh SKhEM LEChENIYa

The article presents the results of the analysis of the clinical efficacy of the therapy of articular syndrome in patients with osteoarthrosis (OA) through the development of pathogenetically substantiated treatment regimens with a differentiated inclusion of drug Chondrogard (chondroitin sulfate) in complex therapy. The study included 76 patients with primary OA who had received only NSAIDs as pathogenetical therapy. In all patients, controlled monitoring of the clinical manifestations of the disease, account of subjective and objective parameters of internal organs and systems were performed within the first 3 days after admission, at 8-10 day, 28-30 day of treatment and 3 months after. Patients were divided into groups: the first group included 46 patients. The second group of a similar age, length and severity of the disease included 30 patients. First group of patients received injected Chondrogard each alternate day intramuscularly over 2 months (№ 30) in addition to conventional treatment. The first three injections were performed at a dose of 1 ml (100 mg), subsequent - at a dose of 2 ml (200 mg). Second group of patients received only conventional therapy. Comparative evaluation of the dynamics of functional parameters of articular syndrome, such as Lequesne index, WOMAC index, indicators of morning stiffness in points and minutes in OA patients under the influence of a combination therapy with Chondrogard and traditional drugs and only traditional therapy clearly show the benefits of a combined treatment regimen with inclusion of Chondrogard.

osteoarthrosis, articular syndrome, non-steroidal anti-inflammatory agents, chondroitin sulfate, Chondrogard